| http://purl.uniprot.org/citations/31119730 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/31119730 | http://www.w3.org/2000/01/rdf-schema#comment | "The prevalence and clinical relevance of TP53 germline mutations in a large unselected breast cancer series are largely unknown. Here, we determined TP53 germline mutations in a large cohort of 10,053 unselected breast cancer patients through multigene panel-based next-generation and/or Sanger sequencing assays. We found that 0.5% of patients (50 cases) carried a pathogenic TP53 germline mutation in this large series of 10,053 unselected breast cancer patients, and the prevalence of TP53 germline mutation was 3.8% in very early onset breast cancer (age ≤30 years) in this large cohort. TP53 mutation carriers were significantly more likely to have early onset cancer (p < 0.001) and bilateral breast cancer (p = 0.03), they and were significantly more likely to respond to carboplatin-based neoadjuvant chemotherapy compared to anthracycline- or taxane-based regimen in terms of pathologic complete response (50% vs. 0%, p = 0.006). At the median follow-up of 54 months, TP53 mutation was an independent unfavorable factor for recurrence-free survival (RFS), distant recurrence-free survival (DRFS), and overall survival (OS) (RFS, adjusted hazard ratio [HR]: 2.24, 95% confidence interval [CI]: 1.15-4.33, p = 0.02; DRFS, adjusted HR: 2.73, 95% CI: 1.41-5.30, p = 0.003; OS, adjusted HR: 4.60, 95% CI: 2.26-9.41, p < 0.001) in multivariate analyses. Our study suggested that TP53 germline mutations occur more frequently in very early onset unselected breast cancer patients; and TP53 germline mutation carriers have a very poor survival and may benefit from carboplatin-based neoadjuvant chemotherapy in unselected breast cancer patients."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.org/dc/terms/identifier | "doi:10.1002/ijc.32424"xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Guo Y."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Li J."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Fan Z."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Xie Y."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Xu Y."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Wang T."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Hu L."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Lin B."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Sheng S."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Fan T."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Yao L."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/author | "Ouyang T."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/date | "2020"xsd:gYear |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/name | "Int J Cancer"xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/pages | "487-495"xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/title | "Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer."xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://purl.uniprot.org/core/volume | "146"xsd:string |
| http://purl.uniprot.org/citations/31119730 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/31119730 |
| http://purl.uniprot.org/citations/31119730 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/31119730 |
| http://purl.uniprot.org/uniprot/#_A0A0A0U7X4-mappedCitation-31119730 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/31119730 |
| http://purl.uniprot.org/uniprot/#_A0A0M4B4Y9-mappedCitation-31119730 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/31119730 |
| http://purl.uniprot.org/uniprot/#_A0A087WXZ1-mappedCitation-31119730 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/31119730 |